<DOC>
	<DOCNO>NCT00121134</DOCNO>
	<brief_summary>The purpose research study study effect ( good bad ) bevacizumab alone , bevacizumab low-dose continuous chemotherapy ( call metronomic chemotherapy ) , bevacizumab capecitabine , cancer . The goal study : - Examine safety drug - See easy difficult treat - Monitor sign recurrent cancer - Look blood marker might indicate treatment work</brief_summary>
	<brief_title>Bevacizumab With Without Cyclophosphamide Methotrexate : A Pilot Study Women With Operable Breast Cancer</brief_title>
	<detailed_description>This study break 4 group ( A , B , C , D ) . Enrollment close group May 2008 . The first forty subject ( Group A ) study treat Bevacizumab , give vein 1-2 hour every 3 week , total approximately 12 month ( 17 cycle ) . Each cycle consist 3 week . The next forty subject ( Group B ) treat Bevacizumab metronomic CM chemotherapy . These subject take cyclophosphamide ( 1 pill mouth every day ) , methotrexate , ( 1 pill take mouth twice day first two day week ) Bevacizumab ( every 3 week ) . The treatment cyclophosphamide , methotrexate Bevacizumab continue approximately 6 month ( 8 cycle ) . Then next 6 month , receive Bevacizumab treatment . The total time study 12 month ( 17 cycle ) . The next forty subject ( Group C ) treat Bevacizumab Capecitabine chemotherapy . These subject take Capecitabine pill twice day 14 day , one week rest , complete 21-day cycle . There total 6 cycle Capecitabine , mean 18 week treatment Capecitabine Bevacizumab . Then receive Bevacizumab treatment ( 11 cycle ) complete 12 month therapy . Total duration treatment 12 month 17 cycle therapy . The last forty subject ( Group D ) treat Bevacizumab Capecitabine chemotherapy different schedule . These subject take Capecitabine pill twice day 7 day , one week rest repeat total 24 week ( 6 cycle ) . Each cycle last 4 week ( 28 day ) . There total 6 cycle Capecitabine , mean 24 week treatment Capecitabine Bevacizumab . Bevacizumab give every two week total 24 week ( 6 cycle ) . Then receive Bevacizumab treatment , every 3 week additional 27 week ( 9 cycle ) complete 12 month therapy . For last 9 cycle Bevacizumab therapy cycle consist 3 week . Total duration treatment 12 month 15 cycle therapy .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Histologically cytologically confirm invasive breast cancer , preoperative stage IIIII per AJCC 6th edition , base baseline evaluation clinical examination and/or breast imaging Patients must complete preoperative ( neoadjuvant ) chemotherapy standard chemotherapy regimen . No chemotherapy plan . Patients must complete definitive resection primary tumor adequate excision gross disease . For patient receive adjuvant radiation therapy , treatment must complete prior initiation protocol therapy . Patients must presence significant residual invasive disease pathologic review follow preoperative chemotherapy . LVEF &gt; institutional limit normal preoperative chemotherapy , assess ECHO nuclear medicine gate study , within 30 day prior initiate protocolbased treatment . ECOG performance status 01 Inadequate organ function , measure laboratory assessment preoperative chemotherapy within 14 day begin protocolbased treatment Patients metastatic disease ineligible . Known HIV infection Patients may pregnant , expect become pregnant , plan conceive child study , breastfeed Uncontrolled intercurrent illness Nonhealing wound major surgical procedure ( breast surgery ) venous access device diagnostic study permit within 28 day prior enrollment History abdominal fistula , GI perforation , intraabdominal abscess , serious , nonhealing wound , ulcer , bone fracture within 6 month prior initiate bevacizumab Patients history arterial thromboembolic event , include transient ischemic attack ( TIA ) , cerebrovascular event ( CVA ) , unstable angina , myocardial infarction ( MI ) within past 6 month . Patients clinically significant peripheral arterial disease also exclude History bleed diathesis coagulopathy History grade 3 4 allergic reaction compound similar chemical biologic composition cyclophosphamide ( alkylating agent ) methotrexate ( antimetabolite ) Prior history malignancy treat without curative intent , exclude nonmelanomatous skin cancer Patients large rapidly accumulate pleural abdominal effusion Current use anticoagulant allow long patient stable dose two week stable INR Chronic therapy full dose aspirin ( &lt; 325 mg/day ) standard nonsteroidal antiinflammatory agent allow Patients may receive investigational agent study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Bevacizumab</keyword>
	<keyword>Metronomic Chemotherapy</keyword>
	<keyword>Breast Cancer Stages II-III</keyword>
	<keyword>Invasive breast cancer stag II-III</keyword>
</DOC>